ScreenerHero

RKV Rakovina Therapeutics Inc.

TSXV · CA · Healthcare · Biotechnology · rakovinatherapeutics.com
0.2700CAD+8.00%Mkt Cap: 4.80M $P/E: —

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap4.80M USD
Enterprise Value7.32M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.32M USD
Revenue/Share—
Last Price0.2700 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-1.71
EV/Revenue—
P/S—
P/B38.57
EPS (TTM)-0.31
EPS (Forward)—
52W Range
0.085052% of range0.4400
52W High0.4400 CAD
52W Low0.0850 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-6212.61%
ROA-204.71%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.24M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-17.25%
Net Debt2.52M USD
Net Debt/EBITDA-0.59
Balance Sheet
Debt/Equity18.58
Current Ratio0.15
Quick Ratio0.10
Book Value/Sh0.0070 CAD
Cash/Share0.0080 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CAD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJun 24, 2025
Analyst Consensus
Rating—
Target (Mean)0.2500 CAD
Upside (mean)-7.4%
Target Range0.2500 CAD – 0.2500 CAD
# Analysts1
Ownership
Shares Out.24.41M
Float21.54M
Insiders5.68%
Institutions0.00%
Short Interest
Short Ratio0.1d
Short % Out.0.01%
Shares Short2.95K
Short (prev mo.)104.00K
Technical
SMA 500.1954 (+38.2%)
SMA 2000.1439 (+87.7%)
Beta-0.10
S&P 52W Chg14.58%
Avg Vol (30d)30.70K
Avg Vol (10d)27.53K
Technical Indicators
RSI (14)61.5
MACD0.0214
MACD Signal0.0240
MACD Hist.-0.0026
BB Upper0.2955 CAD
BB Middle0.2455 CAD
BB Lower0.1955 CAD
BB Width40.77%
ATR (14)0.0230 CAD
Vol Ratio (20d)0.63x